Microsoft Word-33766218-file00

Author Affiliations: Key Lab of Drug Metabolism and Pharmacokinetics, State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, Jiangsu, China (J. S., Y. P., H. W., X. Z., Y. Z., Y. X., F. Z., H.Q., L. S., J. Z., Y. S., K. L., J. A., G. W.) Department of Natural Medicinal Chemistry, China Pharmaceutical University, Nanjing 210009, China (J. L.) Department of Pharmaceutics, University of Washington, Seattle, Washington 98195-7610, USA (R.H) This article has not been copyedited and formatted. The final version may differ from this version. DMD Fast Forward. Published on February 13, 2015 as DOI: 10.1124/dmd.114.060905

[1]  Thuy Tran,et al.  Impact of Physiologically Based Pharmacokinetic Modeling and Simulation in Drug Development , 2013, Drug Metabolism and Disposition.

[2]  L. Wienkers,et al.  Prediction of CYP2D6 Drug Interactions from In Vitro Data: Evidence for Substrate-Dependent Inhibition , 2012, Drug Metabolism and Disposition.

[3]  Wang Guang-ji.  Pharmacokinetic and absolute bioavailability study of Guanfu Base A hydrochloride in Beagle dogs , 2012 .

[4]  M. Wu,et al.  Identification of Phase I and Phase II metabolites of Guanfu base a Hydrochloride in human urine , 2003, European journal of drug metabolism and pharmacokinetics.

[5]  Magang Shou,et al.  Prediction of Human Drug-Drug Interactions from Time-Dependent Inactivation of CYP3A4 in Primary Hepatocytes Using a Population-Based Simulator , 2009, Drug Metabolism and Disposition.

[6]  James J. Gugger,et al.  Delirium in a Patient with Toxic Flecainide Plasma Concentrations: The Role of a Pharmacokinetic Drug Interaction with Paroxetine , 2009, The Annals of pharmacotherapy.

[7]  O. Brørs,et al.  O-demethylation of codeine to morphine inhibited by low-dose levomepromazine , 2009, European Journal of Clinical Pharmacology.

[8]  Yan Li,et al.  Insight into the effects of chiral isomers quinidine and quinine on CYP2D6 inhibition. , 2009, Bioorganic & medicinal chemistry letters.

[9]  N. Waters,et al.  Integrated in Vitro Analysis for the in Vivo Prediction of Cytochrome P450-Mediated Drug-Drug Interactions , 2008, Drug Metabolism and Disposition.

[10]  Alex Phipps,et al.  Application of CYP3A4 in vitro data to predict clinical drug-drug interactions; predictions of compounds as objects of interaction. , 2008, British journal of clinical pharmacology.

[11]  E. Uchida,et al.  Effect of Cinacalcet Hydrochloride, a New Calcimimetic Agent, on the Pharmacokinetics of Dextromethorphan: In Vitro and Clinical Studies , 2007, Journal of clinical pharmacology.

[12]  H. Einolf.  Comparison of different approaches to predict metabolic drug–drug interactions , 2007, Xenobiotica; the fate of foreign compounds in biological systems.

[13]  L J Lesko,et al.  Drug Interaction Studies: Study Design, Data Analysis, and Implications for Dosing and Labeling , 2007, Clinical pharmacology and therapeutics.

[14]  Jun Zhu,et al.  [Effect of Guanfu Base A in patients with ventricular arrhythmias]. , 2006, Zhonghua xin xue guan bing za zhi.

[15]  Torsten Schwede,et al.  BIOINFORMATICS Bioinformatics Advance Access published November 12, 2005 The SWISS-MODEL Workspace: A web-based environment for protein structure homology modelling , 2022 .

[16]  J. Houston,et al.  The Utility of in Vitro Cytochrome P450 Inhibition Data in the Prediction of Drug-Drug Interactions , 2006, Journal of Pharmacology and Experimental Therapeutics.

[17]  M. Sutcliffe,et al.  Why Is Quinidine an Inhibitor of Cytochrome P450 2D6? , 2005, Journal of Biological Chemistry.

[18]  Kiyomi Ito,et al.  IMPACT OF PARALLEL PATHWAYS OF DRUG ELIMINATION AND MULTIPLE CYTOCHROME P450 INVOLVEMENT ON DRUG-DRUG INTERACTIONS: CYP2D6 PARADIGM , 2005, Drug Metabolism and Disposition.

[19]  Magang Shou,et al.  Prediction of pharmacokinetics and drug-drug interactions from in vitro metabolism data. , 2005, Current opinion in drug discovery & development.

[20]  C. von Bahr,et al.  [Combination of serotonergic agents resulted in severe adverse effects]. , 2004, Läkartidningen.

[21]  Kiyomi Ito,et al.  Database analyses for the prediction of in vivo drug-drug interactions from in vitro data. , 2004, British journal of clinical pharmacology.

[22]  J. Marier,et al.  Influence of concomitant quinidine administration on dextromethorphan disposition in rats. , 2004, Journal of veterinary pharmacology and therapeutics.

[23]  L. Bertilsson,et al.  Pharmacogenetic covariation of defective N-oxidation of sparteine and 4-hydroxylation of debrisoquine , 1980, European Journal of Clinical Pharmacology.

[24]  Manuel C. Peitsch,et al.  SWISS-MODEL: an automated protein homology-modeling server , 2003, Nucleic Acids Res..

[25]  D. Greenblatt,et al.  Apparent mechanism-based inhibition of human CYP2D6 in vitro by paroxetine: comparison with fluoxetine and quinidine. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[26]  Guang-Ji Wang,et al.  [Study on the metabolites of guanfu base A hydrochloride in rat urine by high performance liquid chromatograph-mass spectrum]. , 2002, Yao xue xue bao = Acta pharmaceutica Sinica.

[27]  Honglu Zhang,et al.  A method for the simultaneous evaluation of the activities of seven major human drug-metabolizing cytochrome P450s using an in vitro cocktail of probe substrates and fast gradient liquid chromatography tandem mass spectrometry. , 2001, Drug metabolism and disposition: the biological fate of chemicals.

[28]  S. Ling,et al.  Determination of Guan-Fu Base A, a new anti-arrhythmic, in human plasma by gas chromatography and electron-capture detection. , 2000, Journal of Chromatography B: Biomedical Sciences and Applications.

[29]  Wang Guo.  Evaluation of Pharmacokinetics of the Hydrochloride Guanfu Base A , 2000 .

[30]  M. Farré,et al.  Fatal MDMA intoxication , 1999, The Lancet.

[31]  A. Suri,et al.  Inhibition of CYP2D6 by Quinidine and its Effects on the Metabolism of Cilostazol , 1999, Clinical pharmacokinetics.

[32]  S. Imaoka,et al.  Tissue distributions of CYP2D1, 2D2, 2D3 and 2D4 mRNA in rats detected by RT-PCR. , 1998, Biochimica et biophysica acta.

[33]  N. Guex,et al.  SWISS‐MODEL and the Swiss‐Pdb Viewer: An environment for comparative protein modeling , 1997, Electrophoresis.

[34]  G. Tucker,et al.  Potent inhibition of yeast-expressed CYP2D6 by dihydroquinidine, quinidine, and its metabolites. , 1995, Biochemical pharmacology.

[35]  J. Gustafsson,et al.  Cytochromes P450 of the 2D subfamily in rat brain. , 1995, Molecular pharmacology.

[36]  M. Komori.  A novel P450 expressed at the high level in rat brain. , 1993, Biochemical and biophysical research communications.

[37]  M. Eichelbaum,et al.  Enantiomer/enantiomer interaction of (S)- and (R)-propafenone for cytochrome P450IID6-catalyzed 5-hydroxylation: in vitro evaluation of the mechanism. , 1991, Molecular pharmacology.

[38]  A. Boobis,et al.  The specificity of inhibition of debrisoquine 4-hydroxylase activity by quinidine and quinine in the rat is the inverse of that in man. , 1989, Biochemical pharmacology.

[39]  J. Bircher,et al.  Polymorphic dextromethorphan metabolism: Co‐segregation of oxidative O‐demethylation with debrisoquin hydroxylation , 1985, Clinical pharmacology and therapeutics.

[40]  J. W. Barnhart,et al.  The urinary excretion of dextromethorphan and three metabolites in dogs and humans. , 1980, Toxicology and applied pharmacology.

[41]  J. Idle,et al.  POLYMORPHIC HYDROXYLATION OF DEBRISOQUINE IN MAN , 1977, The Lancet.

[42]  R. Martin.  Enzyme and Metabolic Inhibitors. Vol. 1. General Principles of Inhibition. , 1963 .

[43]  J. L. Webb.  General principles of inhibition , 1963 .

[44]  Li J.-H..  Identification of Phase I and Phase II Metabolites of Guanfu Base A Hydrochloride in Human Urine , 2022 .